Shanghai Henlius Biotech (HKSE:02696) Accounts Payable & Accrued Expense : HK$1,525 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Accounts Payable & Accrued Expense?

Shanghai Henlius Biotech's quarterly accounts payable & accrued expense declined from Jun. 2023 (HK$1,928 Mil) to Sep. 2023 (HK$1,705 Mil) and declined from Sep. 2023 (HK$1,705 Mil) to Dec. 2023 (HK$1,525 Mil).

Shanghai Henlius Biotech's annual accounts payable & accrued expense increased from Dec. 2021 (HK$1,095 Mil) to Dec. 2022 (HK$1,979 Mil) but then declined from Dec. 2022 (HK$1,979 Mil) to Dec. 2023 (HK$1,525 Mil).

Shanghai Henlius Biotech Accounts Payable & Accrued Expense Historical Data

The historical data trend for Shanghai Henlius Biotech's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Accounts Payable & Accrued Expense Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

662.93

744.49

1,095.49

1,978.57

1,525.13

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial												-	1,978.57	1,927.62	1,705.39	1,525.13

Shanghai Henlius Biotech Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Shanghai Henlius Biotech (HKSE:02696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Shanghai Henlius Biotech (HKSE:02696) Headlines

No Headlines